SCHEMBL22334232

SCHEMBL22334232

Cc1cc(-c2ncnn2C)c2cccc(OCc3c(Cl)cc(F)cc3[C@H](C)NC(=O)[C@@H](C)O)c2n1

nearest known ligand 0.59

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BDKRB2 P30411 20/20 0.59
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21030190 0.94 BDKRB2 (0.59) BDKRB2CYP3A4
SCHEMBL21031772 0.94 BDKRB2 (0.59) BDKRB2CYP3A4
SCHEMBL22334268 0.94 BDKRB2 (0.59) BDKRB2CYP3A4
SCHEMBL21030341 0.94 BDKRB2 (0.59) BDKRB2CYP3A4
SCHEMBL24426999 0.93 BDKRB2 (0.60) BDKRB2CYP3A4
SCHEMBL21030164 0.92 BDKRB2 (0.56) BDKRB2CYP3A4
SCHEMBL21030531 0.91 BDKRB2 (0.58) BDKRB2CYP3A4
SCHEMBL22334198 0.90 BDKRB2 (0.57) BDKRB2CYP3A4
SCHEMBL21030169 0.90 BDKRB2 (0.57) BDKRB2CYP3A4
SCHEMBL21030335 0.90 BDKRB2 (0.57) BDKRB2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820756-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2023-11-21 US disclosed
US-11820756-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2023-11-21 US disclosed
US-20220135543-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS Pharvaris Netherlands B.V. (NL) 2022-05-05 US disclosed
US-20210017158-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS ANALYTICON DISCOVERY GMBH (DE) 2021-01-21 US disclosed
US-10836748-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2020-11-17 US disclosed
US-20200255405-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS ANALYTICON DISCOVERY GMBH (DE) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210017158-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885CYP3A4 2143/4885
US-20220135543-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885CYP3A4 2143/4885
US-10836748-B2 Bradykinin B2 receptor antagonists BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885CYP3A4 1840/4885
US-11820756-B2 Bradykinin B2 receptor antagonists BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885CYP3A4 1840/4885
US-20200255405-A1 NOVEL BRADYKININ B2 RECEPTOR ANTAGONISTS BDKRB2, BDKRB1, VIPR2 BDKRB2 1/4885CYP3A4 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.